University of Valencia Science Park

Nucleai Expands Leadership Team and Scientific Advisory Board with Pharmaceutical Industry Experts

Retrieved on: 
Wednesday, May 24, 2023
Software, Research, Other Health, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Health Technology, Clinical Trials, Science, Nanotechnology, Biotechnology, Health, Molecular biology, Drug development, University, Rockefeller University, Muller's morphs, BeiGene, Pathology, University of California, Davis, Cancer, Multimedia, Biomarker, Genentech, Bristol Myers Squibb, Weill Cornell Medicine, Traction, Phosphorus, Publication, Lilly, Translational medicine, European, Drug discovery, Merck, University of Valencia Science Park, European Molecular Biology Laboratory, Memorial Sloan Kettering Cancer Center, Pharmaceutical industry, Celgene

Nucleai, a leader in AI-powered spatial biology, today announced the two key appointments to its leadership team and scientific advisory board.

Key Points: 
  • Nucleai, a leader in AI-powered spatial biology, today announced the two key appointments to its leadership team and scientific advisory board.
  • Pharmaceutical industry veteran Oscar Puig, Ph.D. has been named the VP of Translational Medicine & Diagnostics at Nucleai, while Suzana Couto, the Head of Pathology at Neomorph Inc, has been appointed as a scientific advisor for the company.
  • “Their expertise and experience in top pharmaceutical companies perfectly complement Nucleai’s focus on serving the pharmaceutical industry.
  • As part of Nucleai’s scientific advisory board, she will help support the strategic direction and ongoing innovation in the company.

KCAS Bioanalytical and Biomarker Services Announces Growth to Scientific Leadership Team

Retrieved on: 
Tuesday, April 25, 2023
Research, General Health, Pharmaceutical, Data Management, Biometrics, Technology, Genetics, Science, Biotechnology, Other Technology, Other Science, Health, Georgia Tech, Drug development, University, Bureau of Oceans and International Environmental and Scientific Affairs, Senior, Q2, University of Valencia Science Park, Cellular, NEX Group, Infection, ATMP, Multimedia, History, Biomedical engineering, Assistant, PBMC, LIMS, Boehringer Ingelheim, Biomarker, Molecular biology, Eurofins Scientific, Flow cytometry, Biomedicine, KCAS, Immune system, Knowledge, ADC, Growth, Immunogenicity, INRS, Autoimmunity, Management, Fine chemical, Virology, Peptide

In addition, he will continue his role as a key member of our current operations integration team and the Senior Leadership Team.

Key Points: 
  • In addition, he will continue his role as a key member of our current operations integration team and the Senior Leadership Team.
  • “I look forward to this new opportunity to expand further the footprint of the bioanalytical and Biomarkers fields at KCAS.
  • As Executive Director, Cheikh will be responsible for the strategic leadership and management oversight of our Biopharma Services division, positioning the company for continued growth.
  • In addition, he will be an integral member of our global Integration strategy and will continue to be a member of the Senior Leadership Team.

Female Disruptors Announces On-Demand Program, MBA Scholarships, Custom Merch, and More

Retrieved on: 
Monday, February 6, 2023
MBA, Woman, Student, Future, Entrepreneurship, FREE, University, Coffee, University of Valencia Science Park, Movement, VIP, Marketing, Burnout, Nobel Prize, NWA All Access, NFT, History, Weapons in Star Trek, Collection, Rome Business School, Nightclub, Nursing, Management, Department store, Female

ORLANDO, Fla., Feb. 6, 2023 /PRNewswire/ -- Female Disruptors releases its 2023 UNSTOPPABLE Series https://female-disruptors-virtual-summit-2022.heysummit.com/, now streaming in both video and audio experience.

Key Points: 
  • ORLANDO, Fla., Feb. 6, 2023 /PRNewswire/ -- Female Disruptors releases its 2023 UNSTOPPABLE Series https://female-disruptors-virtual-summit-2022.heysummit.com/ , now streaming in both video and audio experience.
  • Female Disruptors invites women from around the world to grab your pink coffee mug, throw on a Female Disruptors' T-shirt, register for your favorite talks, enter to win an MBA, and start binge-watching your future self's course of action.
  • The Female Disruptors UNSTOPPABLE VIP All-Access Pass includes:
    Ducere's MBA Scholarship Opportunity: Automatically entered into a grand prize giveaway.
  • Female Disruptors can also dive into the world of leadership and innovation with a cutting-edge MBA program at Ducere Global Business school.

Graphenano and the University of Valencia revolutionise safety and efficiency in the battery sector by developing the first cell made without metals

Retrieved on: 
Wednesday, February 1, 2023
Sodium, Safety, Copper, Lithium, Nickel, University of Valencia Science Park, European Commission, Representation of the European Commission in Germany, Carbon, Aviation, Atmosphere, Metal, Risk, Silicon, Recycling, Burn, University, Electric battery, Excellence

VALENCIA, Spain, Feb. 01, 2023 (GLOBE NEWSWIRE) -- The project has succeeded in removing the copper, aluminium or steel sheets, the materials generally used in conventional batteries to evacuate the electric current generated. Simultaneously, the metallic tabs (current terminals), usually made of nickel or other metals, which are responsible for transferring the energy from the inside to the outside of the battery, have been eliminated.

Key Points: 
  • Graphenano and the Institute of Molecular Science (ICMol) of the University of Valencia have developed the first battery cell without current collectors or metal terminals.
  • The system, using graphene and carbon nanomaterials instead, enables the manufacture of safer, lighter, and more efficient batteries.
  • Its application in electric cars, aviation, and stationary storage, inter alia, revolutionizes the battery industry.
  • “We have patented a technology that solves the problem of battery safety with a disruptive approach," explains Martín Martínez, CEO of Graphenano.

Maria Martin-Grau, at the University of Valencia, Spain is selected for the 2022 Novelties in Biomarkers award

Retrieved on: 
Thursday, November 17, 2022
Proteomics, University of Valencia Science Park, University Hospitals Cleveland Medical Center, Cardiology, Diagnosis, 2021 Essex County Council election, University, Saint, Infection, Future, Critical care, Marketing, Faculty, Jury, Research, Metabolism, Neurology, Biology, Pharmaceutical industry, Medical imaging, Biomarker

UPPSALA, Sweden, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) is proud to announce the 2022 winner of the young researchers award, Novelties in Biomarkers, Maria Martin-Grau at the University of Valencia, Spain at the Biomarkers of the Future conference in Paris, France.

Key Points: 
  • UPPSALA, Sweden, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) is proud to announce the 2022 winner of the young researchers award, Novelties in Biomarkers, Maria Martin-Grau at the University of Valencia, Spain at the Biomarkers of the Future conference in Paris, France.
  • Novelties in Biomarkers is an annual award established in 2019 by Olink Proteomics with the purpose of encouraging and motivating young scientists in the use of biomarker discovery in their research.
  • The Novelties in Biomarkers award is a pioneering award that sets an example for this entire field of research, and the huge interest in the award is a testament to that.
  • The Novelties in Biomarkers award is Olinks response to address the skills gap and secure future competence within the discipline.

Nouscom Strengthens Leadership Team with the Appointments of Sven Gogov, MD, as Chief Medical Officer and Maria Arce-Tomas, PhD, as VP, Head of Regulatory Affairs

Retrieved on: 
Friday, September 9, 2022
AstraZeneca, Maria, Novartis, University, Regulation, Cancer, Tumor microenvironment, Doctor of Philosophy, Imperial College London, University Health Network, Veteran, GE Healthcare, Clinical research, GSK, Novo Nordisk, University of Valencia Science Park, Abbott, Lead, LinkedIn, Department, CMO, Goal, Pembrolizumab, Bachelor of Pharmacy, MD, Leadership, Biotechnology, Regulatory affairs, Therapy, Immunotherapy, ASCO, Oncology, FDA, Neoplasm, Drug, King's College London, PharmaMar, OSI Pharmaceuticals, Patient, Pharmaceutical industry, Vaccine, Science, Toxicology, Biochemistry, Pharmacy, Takeda

Gogov will join the executive management team and be responsible for the development of the companys clinical project portfolio.

Key Points: 
  • Gogov will join the executive management team and be responsible for the development of the companys clinical project portfolio.
  • "I am also delighted to welcome Maria as the newly appointed Vice President, Head of Regulatory Affairs.
  • Sven Gogov, MD, is an experienced global clinical development leader bringing over 15 years of pharmaceutical oncology experience and regulatory interactionsto Nouscom.
  • Maria joins Nouscom from PharmaMar where she was Global Head of Regulatory Affairs responsible for the entire product portfolio of the PharmaMar Group.

Nouscom Strengthens Leadership Team with the Appointments of Sven Gogov, MD, as Chief Medical Officer and Maria Arce-Tomas, PhD, as VP, Head of Regulatory Affairs

Retrieved on: 
Friday, September 9, 2022
AstraZeneca, Maria, Novartis, University, Regulation, Cancer, Tumor microenvironment, Doctor of Philosophy, Imperial College London, University Health Network, Veteran, GE Healthcare, Clinical research, GSK, Novo Nordisk, University of Valencia Science Park, Abbott, Lead, LinkedIn, Department, CMO, Goal, Pembrolizumab, Bachelor of Pharmacy, MD, Leadership, Biotechnology, Regulatory affairs, Therapy, Immunotherapy, ASCO, Oncology, FDA, Neoplasm, Drug, King's College London, PharmaMar, OSI Pharmaceuticals, Patient, Pharmaceutical industry, Vaccine, Science, Toxicology, Biochemistry, Pharmacy, Takeda

Gogov will join the executive management team and be responsible for the development of the companys clinical project portfolio.

Key Points: 
  • Gogov will join the executive management team and be responsible for the development of the companys clinical project portfolio.
  • "I am also delighted to welcome Maria as the newly appointed Vice President, Head of Regulatory Affairs.
  • Sven Gogov, MD, is an experienced global clinical development leader bringing over 15 years of pharmaceutical oncology experience and regulatory interactionsto Nouscom.
  • Maria joins Nouscom from PharmaMar where she was Global Head of Regulatory Affairs responsible for the entire product portfolio of the PharmaMar Group.

Insigneo Welcomes Advisors from Amerant Bank

Retrieved on: 
Wednesday, October 13, 2021
Consulting, Professional Services, Finance, University of Valencia Science Park, Technology, MBA, Florida International University, Special adviser (UK), Uniform Securities Agent State Law Exam, Merrill (company), Series 7, Wells Fargo Advisors, Mercantil Servicios Financieros, Uniform Investment Adviser Law Exam, Crédit Agricole, RBC, Multimedia, New, Citibank, Saint Mary's University, Morgan Stanley, Banco de Venezuela, Vicente Costa, University, Family, NASD, Financial adviser, Financial services, Drug

Insigneo, the Miami-based Independent Broker-Dealer and Registered Investment Advisory firm, has incorporated new top talent as three Advisors from Amerant Bank join the firms independent network based in Miami.

Key Points: 
  • Insigneo, the Miami-based Independent Broker-Dealer and Registered Investment Advisory firm, has incorporated new top talent as three Advisors from Amerant Bank join the firms independent network based in Miami.
  • View the full release here: https://www.businesswire.com/news/home/20211013005937/en/
    Insigneo Welcomes Advisors from Amerant Bank (Photo: Business Wire)
    Vicent Costa, Ciro Vasquez, and Juan Zenck have decades of experience in the investment advising and wealth management professions.
  • Prior to working for Amerant Bank, Ciro Vasquez also worked at Gibraltar Private Bank & Trust and Banco de Venezuela.
  • Juan Zenck previously worked at Wells Fargo Advisors, Morgan Stanley, and RBC before joining his new team members at Amerant Bank.

Alfasigma inaugurates the new Research & Development center in Pomezia named after its founder Marino Golinelli

Retrieved on: 
Wednesday, September 15, 2021
Biotechnology, R, University, University of Navarra, Research and development, Health, Doctor of Philosophy, Female, Rifaximin, Laboratory, Humanitas, Technology, Pharmacy, Plant, Bologna, Letter, University of Valencia Science Park, Nanotechnology, Tablet, Capsule, Male, Acquisition, Woman, Fine chemical

POMEZIA, Italy, Sept. 15, 2021 /PRNewswire/ -- With an initial investment of over 17 million euros for the development of 5,600m2 of new laboratories dedicated to pharmaceutical technology and analytical chemistry, Alfasigma confirms its commitment to Research and Development. The inauguration of LABIO 4.0 Marino Golinelli is part of a broader corporate strategy of progressive investment in Research and Development (R&D) that allows Alfasigma, one of the first five pharmaceutical companies with Italian capital, to stand out both nationally and internationally for innovation and technological development.

Key Points: 
  • The inauguration of LABIO 4.0 Marino Golinelli is part of a broader corporate strategy of progressive investment in Research and Development (R&D) that allows Alfasigma, one of the first five pharmaceutical companies with Italian capital, to stand out both nationally and internationally for innovation and technological development.
  • "The research and development center of Pomezia, LABIO 4.0, was registered in the name of our founder, Marino Golinelli," declared engineer Stefano Golinelli, president of Alfasigma, "because he has taught us and still teaches us today, over 100 years later, to have faith in the future and in innovation.
  • The company's Research and Development department employs 138 researchers, the majority of whom are women (86 female and 52 male).
  • LABIO 4.0 hosts about half of these which are distributed throughout the R&D centers of Pomezia and Bologna.